pamidronate has been researched along with Kidney Failure in 11 studies
Kidney Failure: A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.
| Excerpt | Relevance | Reference |
|---|---|---|
| " He was treated with seven courses of combined chemotherapy (CDDP + etoposide), until he showed extreme hypercalcemia and acute renal failure." | 7.70 | [A case of lung cancer with hypercalcemia and renal failure responsive to pamidronate]. ( Kametani, T; Koshida, H; Masuda, S, 1999) |
| "Pamidronate (APD) is a drug widely used for the treatment of hypercalcemia of malignancy." | 7.69 | Safety of pamidronate in patients with renal failure and hypercalcemia. ( Flombaum, CD; Machado, CE, 1996) |
| " He was treated with seven courses of combined chemotherapy (CDDP + etoposide), until he showed extreme hypercalcemia and acute renal failure." | 3.70 | [A case of lung cancer with hypercalcemia and renal failure responsive to pamidronate]. ( Kametani, T; Koshida, H; Masuda, S, 1999) |
| "Pamidronate (APD) is a drug widely used for the treatment of hypercalcemia of malignancy." | 3.69 | Safety of pamidronate in patients with renal failure and hypercalcemia. ( Flombaum, CD; Machado, CE, 1996) |
| "Pamidronate is a second-generation bisphosphonate that undergoes negligible biodegradation and is eliminated exclusively by renal excretions." | 1.30 | Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. ( Berenson, JR; Knight, RD; Kowalski, MO; Lau, HS; Rosen, L; Seaman, JJ; Sioufi, A; Vescio, R; Woo, M, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boumans, D | 1 |
| de Vries, PA | 1 |
| Rikken, NE | 1 |
| Laverman, GD | 1 |
| McKay, RR | 1 |
| Lin, X | 1 |
| Perkins, JJ | 1 |
| Heng, DY | 1 |
| Simantov, R | 1 |
| Choueiri, TK | 1 |
| Weinstein, E | 1 |
| Arnold, RM | 1 |
| Yoshizawa, H | 1 |
| Akimoto, T | 1 |
| Nishino, K | 1 |
| Inoue, M | 1 |
| Ito, C | 1 |
| Takeda, S | 1 |
| Kotoda, A | 1 |
| Tamba, K | 1 |
| Yumura, W | 1 |
| Muto, S | 1 |
| Ueda, Y | 1 |
| Kusano, E | 1 |
| Ludwig, H | 1 |
| Zojer, N | 1 |
| Tralongo, P | 1 |
| Repetto, L | 1 |
| Di Mari, A | 1 |
| Mauceri, G | 1 |
| Bollina, R | 1 |
| Ferrau', F | 1 |
| Conti, G | 1 |
| Machado, CE | 1 |
| Flombaum, CD | 1 |
| Berenson, JR | 1 |
| Rosen, L | 1 |
| Vescio, R | 1 |
| Lau, HS | 1 |
| Woo, M | 1 |
| Sioufi, A | 1 |
| Kowalski, MO | 1 |
| Knight, RD | 1 |
| Seaman, JJ | 1 |
| Iggo, N | 1 |
| Winearls, CG | 1 |
| Davies, DR | 1 |
| Koshida, H | 1 |
| Kametani, T | 1 |
| Masuda, S | 1 |
| Lockridge, L | 1 |
| Papac, RJ | 1 |
| Perazella, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation[NCT02074631] | Phase 2 | 80 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pamidronate and Kidney Failure
| Article | Year |
|---|---|
Supportive therapy in multiple myeloma.
Topics: Anemia; Blood Transfusion; Bone Diseases; Calcitonin; Clodronic Acid; Diphosphonates; Erythropoietin | 2011 |
10 other studies available for pamidronate and Kidney Failure
| Article | Year |
|---|---|
Prolonged hypocalcaemia after pamidronate infusion in Riedel's thyroiditis associated hypoparathyroidism.
Topics: Bone Density Conservation Agents; Calcium Carbonate; Dihydrotachysterol; Diphosphonates; Female; Gas | 2013 |
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Dens | 2014 |
Bisphosphonates for bone pain #113.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Neopla | 2010 |
Nephrotic syndrome and renal failure in a patient with metastatic breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Fatal Outcome; Female; Glomerulosclerosis, Focal S | 2011 |
Safety of long-term administration of bisphosphonates in elderly cancer patients.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration S | 2004 |
Safety of pamidronate in patients with renal failure and hypercalcemia.
Topics: Adult; Aged; Aged, 80 and over; Calcium; Creatinine; Diphosphonates; Female; Follow-Up Studies; Huma | 1996 |
Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function.
Topics: Aged; Aged, 80 and over; Area Under Curve; Diphosphonates; Female; Fever; Headache; Humans; Male; Me | 1997 |
The development of cast nephropathy in multiple myeloma.
Topics: Aged; Antineoplastic Agents; Bence Jones Protein; Diphosphonates; Fluid Therapy; Humans; Immunoglobu | 1997 |
[A case of lung cancer with hypercalcemia and renal failure responsive to pamidronate].
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Di | 1999 |
Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.
Topics: Anti-Inflammatory Agents; Diphosphonates; Female; Histiocytosis, Langerhans-Cell; Humans; Kidney Tub | 2002 |